{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:20:44Z","timestamp":1769088044315,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T00:00:00Z","timestamp":1329868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00259-012-2079-y","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T08:36:38Z","timestamp":1329813398000},"page":"864-871","source":"Crossref","is-referenced-by-count":28,"title":["FDG PET\/CT predictive role in follicular lymphoma"],"prefix":"10.1007","volume":"39","author":[{"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Zanoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Fonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Santi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,22]]},"reference":[{"key":"2079_CR1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol 1998;16:2780\u201395.","journal-title":"J Clin Oncol"},{"key":"2079_CR2","doi-asserted-by":"crossref","unstructured":"Bartlett NL, Witzig TE, Gordon L, Beck T, Fehrenbacher L, Kommehl E, et al: 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin\u2019s lymphoma (NHL) patients. ASCO Annual Meeting. Proc Am Soc Clin Oncol 2002;21:Abstract 51.","DOI":"10.1053\/j.seminoncol.2003.10.007"},{"key":"2079_CR3","unstructured":"Nathwani BN, Harris NL, Weisenburger D, et al. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p.\u00a0162\u20137."},{"key":"2079_CR4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258\u201365.","journal-title":"Blood"},{"issue":"1","key":"2079_CR5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2967\/jnumed.108.055376","volume":"50","author":"HA Jacene","year":"2009","unstructured":"Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET\/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009;50(1):8\u201317.","journal-title":"J Nucl Med"},{"key":"2079_CR6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2079_CR7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2001.03169.x","volume":"115","author":"K Spaepen","year":"2001","unstructured":"Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzanini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin\u2019s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272\u20138.","journal-title":"Br J Haematol"},{"key":"2079_CR8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.bjc.6602040","volume":"91","author":"PL Zinzani","year":"2004","unstructured":"Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850\u20134.","journal-title":"Br J Cancer"},{"key":"2079_CR9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/annonc\/mdi271","volume":"16","author":"MJ Reinhardt","year":"2005","unstructured":"Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma patients: when do we really need FDG-PET? Ann Oncol 2005;16:1524\u20139.","journal-title":"Ann Oncol"},{"key":"2079_CR10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Dortz Le","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2079_CR11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","volume":"48","author":"S Bishu","year":"2007","unstructured":"Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:1548\u201355.","journal-title":"Leuk Lymphoma"},{"key":"2079_CR12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","volume":"7","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007;7:291\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2079_CR13","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","volume":"101","author":"R Elstrom","year":"2003","unstructured":"Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875\u2013387.","journal-title":"Blood"},{"issue":"3","key":"2079_CR14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation with lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110(3):652\u20139.","journal-title":"Cancer"},{"key":"2079_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","volume":"107","author":"M Karam","year":"2006","unstructured":"Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175\u201383.","journal-title":"Cancer"},{"key":"2079_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi L, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25\u201330.","journal-title":"J Nucl Med"},{"key":"2079_CR17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S W\u00f6hrer","year":"2006","unstructured":"W\u00f6hrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al: 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780\u20134.","journal-title":"Ann Oncol"},{"issue":"6","key":"2079_CR18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","volume":"12","author":"G Jerusalem","year":"2001","unstructured":"Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin\u2019s lymphoma (NHL). Ann Oncol 2001;12(6):825\u201330.","journal-title":"Ann Oncol"},{"key":"2079_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1102\/1470-7330.2005.0006","volume":"5","author":"RJ Hicks","year":"2005","unstructured":"Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging 2005;5:51\u20137.","journal-title":"Cancer Imaging"},{"key":"2079_CR20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773\u201382.","journal-title":"Eur J Cancer"},{"key":"2079_CR21","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835\u201349.","journal-title":"J Clin Oncol"},{"key":"2079_CR22","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res 1971;31:1860\u20131.","journal-title":"Cancer Res"},{"issue":"11","key":"2079_CR23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1200\/JCO.2008.16.1513","volume":"27","author":"PL Zinzani","year":"2009","unstructured":"Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27(11):1781\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2079_CR24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0609.2008.01051.x","volume":"80","author":"M Hutchings","year":"2008","unstructured":"Hutchings M, Specht L. PET\/CT in the management of haematological malignancies. Eur J Haematol 2008;80(5):369\u201380.","journal-title":"Eur J Haematol"},{"key":"2079_CR25","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of a international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"2079_CR26","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","volume":"23","author":"H Sh\u00f6der","year":"2005","unstructured":"Sh\u00f6der H, Noy A, G\u00f6nen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005;23:4643\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2079_CR27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/10428190903440953","volume":"51","author":"R Watanabe","year":"2010","unstructured":"Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51(2):279\u201383.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2079_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/108497801753131372","volume":"16","author":"F Najjar","year":"2001","unstructured":"Najjar F, Hustinx R, Jerusalem G, Filet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin\u2019s lymphomas (NHL). Cancer Biother Radiopharm 2001;16(4):297\u2013304.","journal-title":"Cancer Biother Radiopharm"},{"key":"2079_CR29","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdq024","volume":"21","author":"E Lopci","year":"2010","unstructured":"Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y90: multicentric study. Ann Oncol 2010;21:1877\u201383.","journal-title":"Ann Oncol"},{"key":"2079_CR30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2169\/internalmedicine.48.1856","volume":"48","author":"O Imataki","year":"2009","unstructured":"Imataki O, Tamai Y, Yokoe K, Furukawa T, Kawakami K. The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center. Intern Med 2009;48:1509\u201313.","journal-title":"Intern Med"},{"key":"2079_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2003.n.013","volume":"4","author":"RH Blum","year":"2003","unstructured":"Blum RH, Seymur JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin\u2019s lymphoma. Clin Lymphoma 2003;4:43\u20139.","journal-title":"Clin Lymphoma"},{"issue":"1","key":"2079_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","volume":"71","author":"A Wirth","year":"2008","unstructured":"Wirth A, Foo M, Seymur JF, MacManus MP, Hicks RJ. Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008;71(1):213\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2079_CR33","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Jankova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-012-2079-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2079-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T01:29:39Z","timestamp":1561339779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-012-2079-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["2079"],"URL":"https:\/\/doi.org\/10.1007\/s00259-012-2079-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,22]]}}}